Key points are not available for this paper at this time.
These findings show, for the first time, a relationship between the occurrence of CTCs and circulating tumor-associated DNA in blood, which, therefore, might become a valuable new source for monitoring metastatic progression in cancer patients.
Schwarzenbach et al. (2009) studied this question.